Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication. Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.
View Top Employees from Sapreme Technologies BVWebsite | https://www.sapreme-technologies.com/ |
Revenue | $5 million |
Employees | 14 (14 on RocketReach) |
Founded | 2016 |
Phone | +31 30 760 0976 |
Technologies |
JavaScript,
HTML,
PHP
+15 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Drug Delivery, Business Services, Drug Discovery |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541713 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular Sapreme Technologies BV employee's phone or email?
The Sapreme Technologies BV annual revenue was $5 million in 2024.
Guy Hermans is the CEO of Sapreme Technologies BV.
14 people are employed at Sapreme Technologies BV.
Sapreme Technologies BV is based in Bilthoven, Utrecht.
The NAICS codes for Sapreme Technologies BV are [54171, 5417, 541713, 541, 54].
The SIC codes for Sapreme Technologies BV are [873, 87].